




UMC Utrecht



MEDICAL RESEARCH
INSTITUTE
OF NEW ZEALAND



CCCTG
Canadian Critical Care
Trials Group



REMAP-CAP

Randomized, Embedded,
Multifactorial Adaptive Platform
trial for Community-Acquired
Pneumonia

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia:

Registry of Interests

REMAP-CAP Registry of Interests Version 2 dated 27 May 2020

1. INTERNATIONAL TRIAL STEERING COMMITTEE

| Investigator | Conflict of Interest statement |
|-----------------------------------|--|
| Professor Derek Angus | Professor Angus reports grants from British Embassy, during the conduct of the study. |
| Professor Yaseen Arabi | Professor Arabi is the principal investigator on a clinical trial for lopinavir/ritonavir and interferon in Middle East respiratory syndrome (MERS) and reports that he was a nonpaid consultant on antiviral active for MERS-coronavirus (CoV) for Gilead Sciences and SAB Biotherapeutics. |
| Ms. Wilma van Bentum-Puijk | Ms. Van Bentum-Puijk has nothing to disclose. |
| Dr. Scott Berry | Dr. Berry reports grants from PREPARE (EU), grants from NHMRC (ANZ), from CIHR (Canada), during the conduct of the study. |
| Ms. Zahra Bhimani | Ms. Bhimani has nothing to disclose. |
| Professor Marc Bonten | Professor Bonten has nothing to disclose. |
| Professor Frank Brunkhorst | Professor Brunkhorst has nothing to disclose. |
| Professor Allen Cheng | Professor Cheng has nothing to disclose. |
| Professor Menno de Jong | Professor de Jong reports other from Vertex, other from Janssen, other from Roche, other from Cidara Therapeutics, outside the submitted work. |

| | |
|----------------------------------|--|
| Dr. Lennie Derde | Dr. Derde reports grants from UMC Utrecht, during the conduct of the study. |
| Professor Herman Goossens | Professor Goossens has nothing to disclose. |
| Professor Anthony Gordon | Professor Gordon reports grants from NIHR Research Professorship, grants from NIHR Imperial Biomedical Research Centre, during the conduct of the study; other from GSK, other from Bristol-Myers Squibb, personal fees from Baxter Healthcare, outside the submitted work. |
| Mr. Cameron Green | Mr. Green has nothing to disclose. |
| Professor Roger Lewis | Professor Lewis reports employment by Berry Consultants, LLC, a statistical consulting firm that specializes in the design, implementation, oversight, and analysis of Bayesian adaptive and platform clinical trials. Berry Consultants, LLC received support from the European PREPARE Consortium during the conduct of this work. |
| Dr. Ed Litton | Dr. Litton has nothing to disclose. |
| Professor John Marshall | Professor Marshall reports grants from Canadian Institutes of Health Research during the conduct of the study; personal fees from AKPA Pharma, other from Adrenomed, personal fees from Baxter, personal fees from Critical Care Medicine, personal fees from Critical Care outside the submitted work; and Chair, International Forum for Acute Care Trialists; Canadian PI, REMAP-CAP. |

| | |
|--|---|
| Dr. Colin McArthur | Dr. McArthur reports grants from Health Research Council of New Zealand, during the conduct of the study. |
| Dr. Shay McGuinness | Dr. McGuinness has nothing to disclose. |
| Associate Professor Srinivas Murthy | Dr. Murthy has nothing to disclose. |
| Professor Alistair Nichol | Dr. Nichol reports grants from EU FP-7 Program, during the conduct of the study. |
| Associate Professor Rachael Parke | Dr. Parke reports grants from Fisher and Paykel Healthcare Ltd, New Zealand, non-financial support from Edwards Lifesciences, outside the submitted work. |
| Ms. Jane Parker | Ms. Parker has nothing to disclose. |
| Professor Kathy Rowan | Prof. Rowan reports grants from European Union, FP7-HEALTH-2013-INNOVATION-1, during the conduct of the study. |
| Ms. Anne Turner | Ms. Turner has nothing to disclose. |
| Professor Steve Webb | Professor Webb reports grants from the National Health and Medical Research Council, during the conduct of the study. |

2. DATA SAFETY MONITORING BOARD

| DSMB Member | Conflict of Interest statement |
|---------------------------------------|--|
| Professor Julian Bion | Professor Bion has nothing to disclose. |
| Dr Jason Connor (Deputy Chair) | Dr. Connor has nothing to disclose. |
| Professor Simon Gates | Professor Gates reports personal fees from University of Birmingham, personal fees from Cochrane Pregnancy and Childbirth Group, University of Liverpool, grants from National Institute of Health Research, other from Warwick Medical School, University of Warwick, outside the submitted work. |
| Dr Victoria Manax (Chair) | Dr. Manax reports other from Bristol Myers-Squibb, outside the submitted work. |
| Professor Tom van der Poll | Professor van der Poll has nothing to disclose. |
| Professor John Reynolds | Professor Reynolds reports other from Novartis AG, outside the submitted work; and his employer, Alfred Health, receives funds to cover my inputs to the design, management and analysis of clinical trials funded by pharmaceutical companies (Abbvie, Amgen, BMS, Celgene, GSK, Helsinn, Hemalogix, Johnson & Johnson, Novartis, Pfizer, Phebra and Roche) as well as state and federal government agencies in Australia (VCA, MRFF and NHMRC). Funding is also received from the Australasian Leukemia & Lymphoma Group |

| | |
|--|--|
| | (ALLG) and the Leukemia & Lymphoma Society (LLS, USA). |
|--|--|